SCHEMBL29627013

SCHEMBL29627013

CC(CCCCCCCO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C)CC(=O)O

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 10/20 0.37
PPARA Q07869 1/20 0.37
SMYD2 Q9NRG4 1/20 0.37
CYP3A4 P08684 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31246231 0.90 SMYD2 (0.39) PPARDPPARASMYD2CYP3A4HTT
SCHEMBL28950526 0.88 GPR84 (0.43) SMYD2CYP3A4HTTSMN1; SMN2
SCHEMBL28950527 0.88 GPR84 (0.43) SMYD2CYP3A4HTTSMN1; SMN2
SCHEMBL29627016 0.87 FAAH (0.49) SMYD2CYP3A4HTTSMN1; SMN2
SCHEMBL19582827 0.86 FAAH (0.36) SMYD2CYP3A4HTTSMN1; SMN2HDAC3
SCHEMBL29113324 0.84 MMP2 (0.41)
SCHEMBL18082177 0.83 SMYD2 (0.38) PPARDPPARASMYD2CYP3A4HTT
SCHEMBL18641636 0.83 SMYD2 (0.40) SMYD2CYP3A4HTTSMN1; SMN2
SCHEMBL18664981 0.83 SMYD2 (0.40) SMYD2CYP3A4HTTSMN1; SMN2
SCHEMBL17747703 0.82 CPA1 (0.41) SMYD2CYP3A4HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260102373-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2026-04-16 US disclosed
US-20250352510-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2025-11-20 US disclosed
US-20250213522-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2025-07-03 US disclosed
EP-4578865-A2 LYMPH DIRECTING PRODRUGS Monash University (AU) 2025-07-02 EP disclosed
EP-3180349-B1 LYMPH DIRECTING PRODRUGS AND THERAPEUTIC USES THEREOF UNIV MONASH (AU) 2025-03-12 EP disclosed
CN-117164657-A Prodrugs of directed lymphatics 莫纳什大学 2023-12-05 CN disclosed
CN-117088931-A Prodrugs of directed lymphatics 莫纳什大学 2023-11-21 CN disclosed
CN-106715456-B Prodrugs of directed lymphatics 莫纳什大学 2023-08-29 CN disclosed
US-20220211664-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2022-07-07 US disclosed
US-11311512-B2 Lymph directing prodrugs MONASH UNIVERSITY (AU) 2022-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220211664-A1 LYMPH DIRECTING PRODRUGS LTA, ABCB11, LYN PPARD 3381/4885PPARA 2230/4885SMYD2 2866/4885
US-11311512-B2 Lymph directing prodrugs LTA, ABCB11, LYN PPARD 3381/4885PPARA 2230/4885SMYD2 2866/4885
US-20260102373-A1 LYMPH DIRECTING PRODRUGS MALT1, CES1, LIPA PPARD 1891/4885PPARA 994/4885SMYD2 1500/4885
US-20250213522-A1 LYMPH DIRECTING PRODRUGS LTA, ABCB11, LYN PPARD 3381/4885PPARA 2230/4885SMYD2 2866/4885
US-20250352510-A1 LYMPH DIRECTING PRODRUGS LTA, ABCB11, LYN PPARD 3381/4885PPARA 2230/4885SMYD2 2866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.